New Study Finds Blood Protein May Predict Parkinson’s Disability

A recent study suggests that levels of a blood protein called fibronectin could help predict when people with Parkinson’s disease might face major disability milestones, such as needing a wheelchair or experiencing severe dementia. What is Fibronectin? Fibronectin is a protein that helps cells stick together, playing a key role in wound healing. Researchers found that lower levels of this protein in the blood are linked to faster progression of disability in Parkinson’s. Key Findings: Lower fibronectin levels at the start of the study were tied to a higher risk of reaching major disabilities sooner. Patients with higher fibronectin levels (above 197.6 mg/L) took longer to hit these disability milestones. Fibronectin levels drop faster in patients with rapidly progressing Parkinson’s, providing clues about disease progression. How It Works Parkinson’s progression can vary greatly between individuals, making it hard to predict outcomes. This study tested 19 inflammation-related markers in the blood of Parkinson’s patients to see which could predict disability milestones. Fibronectin emerged as the best predictor. Additionally, fibronectin levels were linked to other Parkinson’s-related changes: Lower fibronectin was associated with higher levels of toxic proteins in the blood. It was also tied to a weaker blood-brain barrier, a protective layer that becomes more permeable as Parkinson’s progresses. Why This Matters This discovery could make fibronectin a valuable tool for doctors to: Predict how quickly Parkinson’s might progress for individual patients. Monitor disease progression over time. Measure the effectiveness of treatments in clinical trials aiming to delay or prevent disabilities in Parkinson’s. What’s Next? The study’s results highlight the potential of fibronectin as a simple blood test to help guide treatment and care for Parkinson’s patients. While more research is needed, this finding offers hope for better understanding and managing the disease’s progression.